PMV Pharmaceuticals, Inc. - Amendment No. 4 to Schedule 13D

This filing, Amendment No. 4 to Schedule 13D, reports a significant change in beneficial ownership for OrbiMed Advisors LLC and OrbiMed Capital GP V LLC (collectively, the "Reporting Persons") concerning PMV Pharmaceuticals, Inc. The Reporting Persons have ceased to be beneficial owners of more than 5% of the company's outstanding shares. This is an exit filing, indicating the Reporting Persons have sold their holdings. Specifically, on February 27, 2026, OPI V sold 505,000 shares at $1.62, and on March 2, 2026, OPI V sold an additional 4,470,291 shares at the same price. As a result, OrbiMed Private Investments V, LP (OPI V) now holds 0 shares, representing 0.0% ownership. The filing also details the ongoing rights and agreements between the parties, including investors' rights regarding demand and piggyback registrations, though these are now largely not applicable due to the divestiture.